Blood Matters.™     
View Archive
2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
DateSubject
December, 23 2015 Cerus Announces Rhode Island Blood Center Enters into Agreement for the Use of INTERCEPT Platelets and Plasma
View Release
December, 10 2015 Cerus Announces Agreement with the National Transfusiology Center of Mongolia for the Use of INTERCEPT Platelets and Plasma
View Release
December, 09 2015 Cerus Announces Agência Nacional de Vigilância Sanitária Approval of the INTERCEPT Blood System for Platelets and Plasma in Brazil
View Release
December, 08 2015 First Patient Enrolled in Cerus’ Phase IV PIPER Study
View Release
December, 07 2015 Cerus and Shepeard Community Blood Center Enter into Agreement for the Use of INTERCEPT Platelets and Plasma
View Release
December, 04 2015 Cerus Announces Mississippi Valley Regional Blood Center Enters Into Agreement for the Use of INTERCEPT Platelets and Plasma
View Release
December, 02 2015 Cerus Announces Collaboration Agreement With Haemonetics for the Use of Acrodose Platelet Kits With the INTERCEPT Blood System for Platelets
View Release
December, 01 2015 Cerus and The Community Blood Center Enter into Agreement for the Use of INTERCEPT Platelets and Plasma
View Release
November, 05 2015 Cerus Corporation Reports Third Quarter 2015 Results
View Release
November, 05 2015 Cerus and OneBlood Enter into Agreement for the Use of INTERCEPT Platelets and Plasma
View Release
November, 03 2015 Cerus to Present at the Stephens 2015 Fall Investment Conference on November 10, 2015
View Release
November, 02 2015 Cerus Corporation Announces CMS Issuance of Permanent P-Codes for Outpatient Hospital Billing of Pathogen-Reduced Platelets and Plasma
View Release
October, 26 2015 Cerus to Release Third Quarter 2015 Results on November 5, 2015
View Release
October, 21 2015 Cerus Corporation Announces New Agreement With Fresenius Kabi for the Production of INTERCEPT Blood System Kits
View Release
October, 06 2015 Cerus and the Community Blood Center of the Carolinas Enter into Agreement for the Use of INTERCEPT Platelets and Plasma
View Release
September, 10 2015 Cerus to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 17, 2015
View Release
September, 02 2015 Cerus to Present at the Baird 2015 Healthcare Conference on September 9, 2015
View Release
August, 06 2015 Cerus Corporation Reports Second Quarter 2015 Results
View Release
August, 04 2015 Cerus to Present at the 2015 Wedbush PacGrow Healthcare Conference on August 11, 2015
View Release
July, 21 2015 Cerus and Unyts Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma
View Release
July, 13 2015 Cerus and Bonfils Blood Center Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma
View Release
July, 06 2015 Cerus to Release Second Quarter 2015 Results on August 6, 2015
View Release
July, 01 2015 Cerus to Present at Cantor Fitzgerald’s Inaugural Healthcare Conference on July 8, 2015
View Release
June, 29 2015 First INTERCEPT Pathogen Reduced Platelet Units Produced in the Continental US
View Release
June, 08 2015 Richard J. Benjamin, MD PhD Appointed as Cerus Corporation’s New Chief Medical Officer
View Release
May, 05 2015 Cerus Corporation Reports First Quarter 2015 Results
View Release
April, 27 2015 Cerus to Present at AABB Symposium on Pathogen-Reduced Components
View Release
April, 22 2015 Cerus to Release First Quarter 2015 Results on May 5, 2015
View Release
March, 16 2015 First Patient Enrolled in Cerus' TRUE Study With the American Red Cross to Address Chikungunya and Dengue Blood Safety Risks With Pathogen Reduced Platelets
View Release
February, 27 2015 Cerus Signs INTERCEPT Platelet Agreement With Sweden’s Largest Blood Product Supplier
View Release
February, 26 2015 Cerus Corporation Reports Fourth Quarter and Year-End 2014 Results
View Release
February, 24 2015 Cerus to Present at the Cowen and Company 35th Annual Health Care Conference on March 3, 2015
View Release
February, 13 2015 Cerus to Release Fourth Quarter 2014 Results on February 26, 2015
View Release
February, 05 2015 Cerus and SunCoast Blood Bank Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma
View Release
February, 04 2015 Cerus and Blood Bank of Delmarva Enter into Agreement for the Use of INTERCEPT Platelets and Plasma
View Release
January, 07 2015 Cerus Prices $70.0 Million Public Offering of Common Stock
View Release
January, 05 2015 Cerus Announces Proposed Public Offering of Common Stock
View Release
January, 05 2015 Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint
View Release

Links

    Global Headquarters

  • 2550 Stanwell Drive
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600

Email Alerts

Alerts are emailed to you when certain new company information is posted to this site.

Sign up for Email Alerts

Copyright (c) 2019 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. InterSol and Amicus are trademarks of Fenwal, Inc.